Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Active Not Recruiting NCT05697107

Ripretinib in Chinese Patients With Advanced GIST: a Real World Study

Conditions: Gastrointestinal Stromal Tumors

Sex: All

Ages: 18 Years – N/A

Enrollment: 308

Sponsor: Peking University

Location: China

Summary

to evaluate the clinical efficacy, safety and predictive factors of ripetinib in Chinese patients with advanced GIST in the real world

Eligibility Criteria

Inclusion Criteria:-≥18 years oldHistologically confirmed gastrointestinal stromal tumor (GIST)At least one measurable lesion (mRECIST v1.1)Received or receiving ripretinib treatmentExclusion Criteria:Patients who received <1 cycle of ripretinib treatmentMedical records are incomplete

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05697107). StuddyBuddy aggregates publicly available trial information.